



Eagle Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference as follows:

Date: Wednesday, January 13, 2021

Time: 4:30 p.m. Eastern Standard Time

Webcast: https://ipmorgan.metameetings.net/events/healthcare21/sessions/35699-eagle-pharmaceuticals/webcast?gpu_only=true&kiosk=true

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company's website at www.eagleus.com, under the Investors Section.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include RYANODEX[®], BENDEKA[®], BELRAPZO[®], and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle's website at www.eagleus.com.

Investor Relations for Eagle Pharmaceuticals, Inc.:

Lisa M. Wilson

In-Site Communications, Inc.

T: 212-452-2793

E: lwilson@insitecony.com

Source: Eagle Pharmaceuticals, Inc.